Last reviewed · How we verify
NCT04406233
Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19
trial in SARS-CoV 2 in 176 participants. Status unknown.
23 May 2022
Quick facts
| Lead sponsor | University of Sao Paulo |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 176 |
| Start date | 23 May 2020 |
| Primary completion | 23 May 2022 |
| Estimated completion | 23 May 2022 |
| Sites | 1 location across Brazil |
Conditions studied
- SARS-CoV 2 — all drugs for SARS-CoV 2 →
Sponsor
University of Sao Paulo
Who can join
18 and older, any sex, with SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The severe acute respiratory syndrome induced by the new coronavirus (SARS-CoV-2) has been declared a worldwide pandemic. Identifying common characteristics of the disease is crucial to promote a better prognosis for patients and to reduce the occurrence of medical complications, the time to medical discharge and mortality rates. Muscle mass and strength are recognized predictive measures of medical complications and mortality in different populations, but it is still unclear whether these also applies to patients with SARS-CoV-2. Therefore, this study will investigate whether muscle mass and/or muscle strength are predictors of the time until medical discharge of patients hospitalized with SARS-CoV-2. Our working hypothesis is that muscle mass and/or muscle strength are predictive measurements of the time until medical discharge of patients hospitalized with SARS-CoV-2
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04406233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV 2
Currently open trials in the same condition.
- NCT04853004 — Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations · active not recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
Other University of Sao Paulo trials
Trials by the same sponsor.
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07522554 — Lavender and Lemongrass Aromatherapy for Pain and Anxiety in Labor: A Randomized Trial · NA · active not recruiting
- NCT07479940 — Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters · NA · active not recruiting
- NCT07445178 — Piecemeal Resection and Advanced Histology Independently Predict Local Recurrence After Colorectal Snare-based Endoscopi · completed
- NCT07170007 — Physiotherapeutic Protocol Compared to Usual Care in the Treatment of Primiparas After Perineal Trauma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04406233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo
- Last refreshed: 28 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04406233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing